Saturday 17 October 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 89.7% and free cash flow fell 166.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
25.17
2.20
−8.04%
Follow VKTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
28.34 | 9.33 | 5.72 | 4.72 |
Net Debt/EBITDA |
7.11 | 4.24 | 3.65 | 3.76 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.04 | 0.54 | 0.72 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.84) | (0.76) | (0.99) | (1.08) | |
Cash per Share |
6.36 | 6.26 | 5.22 | 4.31 | |
Shareholders Equity per Share |
6.35 | 5.67 | 4.34 | 3.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.35 | 5.67 | 4.34 | 3.51 | |
Free Cash Flow |
(94.00) | (85.29) | (113.98) | (125.17) | |
Working Capital |
712.64 | 638.93 | 501.88 | 407.91 | |
Net Current Asset Value |
712.32 | 638.93 | 501.88 | 403.98 | |
| Other line items | |||||
Quick Ratio |
27.41 | 9.21 | 5.67 | 4.57 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.84) | (0.76) | (0.99) | (1.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.33 | 31.53 | 37.44 | 37.25 | |
Average Assets |
838.65 | 812.03 | 737.62 | 674.87 | |
Average Common Equity |
812.24 | 759.67 | 674.42 | 601.89 |
Columns are period end dates